Evidence map›Paper›PMID 41134065›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Anti-PD-1 Nanobody-Armored MSLN CAR-T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies.

Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yan SunSchool of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
Haochen YangState Key Laboratory of Molecular Biology, Shanghai Science Research Center, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.
Qing XuDepartment of Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Tongji University, Shanghai, 200072, China.
Xingya LiDepartment of Oncology, Department of Gynecological Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jinxing LouSchool of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
Jianchun DuanDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.
Jiachen XuDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.
Zhuqing LiuDepartment of Oncology, Shanghai Tenth People's Hospital, Tongji University Cancer Center, Tongji University, Shanghai, 200072, China.
Yong XiaSchool of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
Zhicai LinSchool of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
Linlin LiDepartment of Oncology, Department of Gynecological Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Dan SunShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Jiaguo LiSchool of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
Tao LiuShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Jun GuoShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Wenfeng XuShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Weimin ZhuShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Yi LiuShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Boyang SunDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.
Jia ZhongDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.
Lijie RongShanghai Cell Therapy Group Co. Ltd, Shanghai, 201805, China.
Qijun QianSchool of Medicine, Shanghai Mengchao Cancer Hospital, Shanghai University, Shanghai, 200444, China.
Chenqi XuState Key Laboratory of Molecular Biology, Shanghai Science Research Center, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China.
Jie WangDepartment of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021, China.ORCID https://orcid.org/0000-0002-5602-0487

Funding

Beijing Nova Program 20220484119CAS Young Scientists in Basic Research Program YSBR-014Ministry of Science and Technology of the PRC, National Key Research Plan 2019YFC1316202National key R&D program of China 2022YFC2505000Natural Science Foundation of Beijing Municipality 7242114Shanghai Pilot Program for Basic Research - Chinese Academy of Sciences, the Shanghai Branch JCYJ-SHFY-2022-009
6 · The paper itself

Abstract

Malignant mesothelioma (MM) is an aggressive and currently incurable cancer with limited therapeutic options. Due to the high expression of mesothelin in this cancer, anti-PD-1 nanobody-armored mesothelin-targeting CAR-T (NAC-T) cells are developed. Based on the enhanced anti-tumor activity observed in preclinical in vitro and in vivo studies, a first-in-human clinical trial is initiated. Eleven patients with malignant mesothelioma who have progressed after standard therapies receive intravenous infusions of 5-20 × 10

Indexed as

Immunotherapy, AdoptiveMesothelinMesotheliomaMesothelioma, MalignantProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenAgedAnimalsFemaleHumansMaleMiddle AgedMesothelinMSLN protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenCAR‐Tfirst‐in‐human studymalignant mesotheliomaNAC‐T

Identifiers

PMID41134065
PMCPMC13292173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.